Rationale: FK506 binding protein (FKBP)12 is a known cis-trans peptidyl prolyl isomerase and highly expressed in the heart. Its role in regulating postnatal cardiac function remains largely unknown.
F K506 binding protein (FKBP)12 is a major binding protein for immunosuppressant FK506 and is a 12-kDa cis-trans peptidyl prolyl isomerase belonging to the immunophilin family. 1 FKBP12.6, another family member, shares 85% amino acid homology with FKBP12. 2 Despite their close similarity, FKBP12 and FKBP12.6 apparently have different physiological functions. 3, 4 Previously, FKBP12 has been suggested to interact with skeletal muscle calcium release channel ryanodine receptor type 1 (RyR1) and to play an important role in modulating skeletal muscle excitationcontraction coupling, 5 whereas FKBP12.6 has a much higher affinity to cardiac ryanodine receptor (RyR2) and is more relevant to regulating RyR2 function and calcium release in cardiomyocytes. 2, 6 Mice deficient in FKBP12 exhibit multiple cardiac defects, including ventricular hypertrabeculation, noncompaction, and ventricular septal defect, and die in utero. 4 Although FKBP12 is indispensable to mammalian cardiac development, its role in the postnatal heart is largely unknown, in spite of the fact that FKBP12 is more abundantly expressed in cardiomyocytes than FKBP12.6. 2, 6, 7 To investigate the physiological role of FKBP12 in the heart, we created and analyzed cardiomyocyte-restricted FKBP12 conditional knockout (FKBP12 f/f /␣MyHC-Cre) and FKBP12 overexpression transgenic (␣MyHC-FKBP12) mice. Our findings provide novel insight into the critical role of FKBP12 in regulating and maintaining heart rhythm via the regulation of voltage-gated Na ϩ channels.
Methods
An expanded Methods section is available in the Online Data Supplement at http://circres.ahajournals.org.
Generation of Cardiomyocyte-Specific FKBP12 Transgenic and Knockout Mice
␣-Myosin heavy chain (␣MyHC) promoter was placed at 5Ј of a human FKBP12 cDNA ( Figure 1A ). The procedures that generated ␣MyHC-FKBP12 transgenic mice were carried out as described previously. 8 To achieve spatially and temporally regulated FKBP12 knockout via the Cre-loxP system, 2 loxP sites were placed flanking exon 3 of the mouse FKBP12 gene ( Figure 5A ).
Electrophysiological and Optical Mapping Study in Langendorff-Perfused Hearts
The heart was perfused with oxygenated Tyrode's solution. Electrophysiological study was performed with a 2-F octapolar electrode catheter. Transmembrane action potentials (APs) were recorded with standard glass microelectrodes. Optical mapping of voltagedependent signals was performed using di-4-ANEPPS. Ventricular conduction velocities in the longitudinal (CV max ) and transverse (CV min ) directions were measured during pacing at the center of the left ventricular lateral wall. 9
Whole-Cell Patch Techniques
Transsarcolemmal currents were recorded using the standard wholecell patch-clamp technique.
Results

Generation of Cardiomyocyte-Restricted FKBP12 Transgenic Mice
To determine the role of FKBP12 in the heart, we generated cardiomyocyte-restricted FKBP12 transgenic mice (␣MyHC-FKBP12) ( Figure 1A ). Three independent transgenic lines (ie, nos. 4, 6, and 12) were generated. Western blot analyses demonstrated that all 3 transgenic lines exhibited an Ϸ9-fold increase in steady-state FKBP12 protein levels in the hearts as compared with their nontransgenic controls ( Figure 1B ). All transgenic mice showed normal development and growth. However, 49 of 130 ␣MyHC-FKBP12 transgenic mice (Ϸ38%) died suddenly. All three transgenic lines demonstrated similarities in the rates of sudden death and manifestation of electrocardiographic abnormalities (see below). Deaths occurred predominantly between 4 to 6 weeks of age and were not preceded by any overt signs of illness. There was no sudden death in 151 nontransgenic littermate controls.
At 2 months of age, the heart weight versus body weight ratio in ␣MyHC-FKBP12 mice was not different from that in nontransgenic littermates. The ventricles of ␣MyHC-FKBP12 hearts appeared normal grossly and microscopically ( Figure 1C ). However, the atria of ␣MyHC-FKBP12 hearts in all three transgenic lines were significantly enlarged compared with nontransgenic littermates at 6 to 8 weeks of age ( Figure 1C ). Transthoracic M-mode echocardiography showed that the left ventricular dimensions and contractile function of ␣MyHC-FKBP12 hearts (nϭ16) were not significantly altered compared with those of nontransgenic littermates (nϭ15) ( Figure 1D ). Interestingly, however, ␣MyHC-FKBP12 mice in all three transgenic lines exhibited bradyarrhythmias. This unexpected finding suggested the possibility that the sudden deaths in the transgenic mice were caused by cardiac arrhythmias, prompting us to study their electrophysiological phenotype in more detail. As all three transgenic lines gave rise to identical electrocardiographic phenotypes, we mainly used the transgenic line #4 for the following in-depth investigation.
Cardiac Conduction Disturbances in ␣MyHC-FKBP12 Mice
Surface ECGs recorded from anesthetized ␣MyHC-FKBP12 mice revealed significantly prolonged PP interval, P wave duration, PQ interval, and QRS duration as compared with nontransgenic mice (Figure 2A ; QT intervals were not measured because of difficulty in defining the QT intervals in mice 10 ). Eighty-two of 105 ␣MyHC-FKBP12 mice studied presented with various degrees of atrioventricular (AV) conduction block. Ambulatory ECG recordings in seven ␣MyHC-FKBP12 mice demonstrated intermittent complete AV block, whereas AV conduction in five nontransgenic littermates was unaltered ( Figure 2B ).
To further characterize conduction in ␣MyHC-FKBP12 hearts, we performed electrophysiological studies in Langendorff-perfused hearts. Compared with nontransgenic littermate controls (nϭ8), ␣MyHC-FKBP12 hearts (nϭ9) had significant prolongations of the atrial-His and His-ventricular intervals, the pacing cycle length at which Wenckebach-type AV block occurred, and the effective refractory period of the AV node, indicating depressed intraatrial, AV, and intraventricular conduction ( Figure 2C ). We also measured conduction velocity in left ventricular epicardium using the optical mapping technique. The conduction velocity in ␣MyHC-FKBP12 transgenic hearts was significantly slower than that in nontransgenic hearts ( Figure 2D ), but the degree of conduction anisotropy was not changed. Finally, microelectrode measurements of transmembrane AP from the left ventricular epicardium of isolated hearts revealed deceleration of the maximal phase 0 upstroke velocity, (dV/dt) max , and a marked AP prolongation in transgenic hearts ( Figure 3A ). Taken together, chronic FKBP12 overexpression was associated with abnormal conduction and repolarization.
Non-standard Abbreviations and Acronyms
Altered I Na in ␣MyHC-FKBP12 Cardiomyocytes
A major determinant of electric conduction is the magnitude of Na ϩ influx through voltage-gated Na ϩ channels during the initial fast membrane depolarization. 11 Accordingly, using the whole-cell voltage-clamp technique, we compared the density and properties of the macroscopic voltage-gated Na ϩ current (I Na ) in ␣MyHC-FKPB12 and wild-type cardiomyocytes. To avoid the potentially confounding effects of structural abnormalities seen in ␣MyHC-FKBP12 atria ( Figure 1C ), current measurements were restricted to ventricular cardiomyocytes. Figure 3B shows representative families of whole-cell I Na in a nontransgenic and an ␣MyHC-FKBP12 ventricular cardiomyocyte, respectively. Mean peak I Na density was dramatically reduced (Ϸ80%) in ␣MyHC-FKBP12 cardiomyocytes compared with their nontransgenic counterparts, whereas mean whole-cell capacitance was not significantly altered. Peak I Na densities were maximal at Ϫ25 mV and Ϫ5 mV in wild-type and transgenic myocytes, respectively ( Figure 3C ). FKBP12 overexpression shifted the peak I Na -V curve to more positive potentials, indicating that the number of Na ϩ channels activated at a given membrane voltage was reduced. In addition, we found that recovery of I Na from inactivation was delayed in ␣MyHC-FKBP12 cardiomyocytes ( Figure 3D ). Because I Na completely recovered within less than 100 ms in cardiomyocytes of either genotype, the interpulse interval used for measurements of the peak I Na -V relationship (1 second) was sufficient to allow for complete I Na recovery between consecutive voltage pulses. Thus, differences in I Na recovery did not contribute to the reduction in peak I Na . Steady-state I Na activation curves were generated and were fitted by the Boltzmann equation (2 right curves in Figure  3E ). FKBP12 overexpression caused a positive shift in I Na activation and the slope factor for activation was altered (Online Table I ). Steady-state inactivation was determined using a standard double-pulse protocol and the data were fitted by a Boltzmann equation (2 left curves in Figure 3E ). FKBP12 overexpression resulted in a positive shift in steadystate I Na inactivation, indicating that the fraction of available Na ϩ channels at a given membrane potential was increased. The slope factor of steady-state inactivation was not altered. FKBP12 overexpression significantly slowed both the early and late component of I Na inactivation compared with those of wild-type cardiomyocytes ( Figure 3F ; Online Table II) . Tetrodotoxin (TTX) inhibition of peak I Na followed single Hill curves with k d values of 1.2 and 1.6 mol/L for nontransgenic and transgenic cardiomyocytes, respectively (PϾ0.05) ( Figure 4A ). This is consistent with published values of the k d for the TTX-resistant, ie, cardiac, I Na . 12 Figure 4B shows that FKBP12 overexpression enhances a persistent and TTX-resistant (3 mol/L) late I Na component. Quantitative (q)RT-PCR, Western blot, and immunofluorescence staining demonstrated that Na v 1.5, the pore-forming ␣-subunit of the cardiac, ie, TTX-resistant, voltage-gate Na ϩ channel, was significantly reduced in ␣MyHC-FKBP12 hearts as compared with nontrans-genic hearts, suggesting that the reduction in I Na is partly attributable to lowered Na v 1.5 expression ( Figure 4C ).
K ؉ Currents, L-Type Ca 2؉ Currents, and [Ca 2؉ ] i Transients in ␣MyHC-FKBP12 Cardiomyocytes
It has been shown that FK506 has multiple effects on ion channels, which raised the possibility that FKBP12 overexpression also alters other ionic currents. Accordingly, we assessed the voltage dependence of the inwardly rectifying K ϩ current (I K1 ), the transient outward K ϩ current (I to ), and sustained K ϩ current (I Ksus ) in ␣MyHC-FKBP12 ventricular myocytes. FKBP12 overexpression did not significantly alter I K1 and I to densities over the range of membrane potentials tested, whereas it slightly increased I Ksus density (Online Figure I, A) . Because increased I Ksus would be expected to shorten action potential duration (APD), we conclude that the APD prolongation observed in ␣MyHC-FKBP12 cardiomyocytes did not result from altered potassium current densities.
In addition, we simultaneously measured I Ca,L and [Ca 2ϩ ] i transients (Online Figure I, B ). Peak I Ca,L was reduced by 18% in transgenic cells compared with littermate control cells. A decrease in the amplitude of [Ca 2ϩ ] i transient was also observed, which seemed to be secondary to changes in I Ca,L , because of the similar voltage-dependent reduction in peak amplitudes of I Ca,L and [Ca 2ϩ ] i . Similarly, a reduction of I Ca,L would be expected to shorten, rather than prolong, APD and thus is not likely to underlie the delay in ventricular repolarization in the transgenic cardiomyocytes.
Generation of Cardiomyocyte-Restricted FKBP12 Conditional Knockout Mice
Previously, we have shown that FKBP12-deficient mice exhibit severe defects in cardiac ventricular development and die in utero. 4 To determine whether this developmental defect resulted from a cardiomyocyte autonomous origin, we generated FKBP12 cardiomyocyte-restricted conditional knockout (FKBP12 f/f /␣MyHC-Cre) mice using the Cre-loxP strategy ( Figure 5A ). ␣MyHC-Cre mice were used to ablate FKBP12 in cardiomyocytes. qRT-PCR and Western blot analyses confirmed that FKBP12 was ablated in adult mutant hearts ( Figure 5B and 5C ). FKBP12 f/f /␣MyHC-Cre mice exhibited normal cardiac development ( Figure 6A ) and survived to adulthood. Echocardiography showed comparable left ventricular dimensions and contractile function in mutant and littermate control hearts ( Figure 6B) . Thus, the developmental defects in FKBP12-deficient mice seemed to result from a noncardiomyocyte origin. This finding was consistent with a previous report by Hamilton and colleagues. 13 Importantly, the absence of gross structural abnormalities enabled us to directly assess the effect of FKBP12 deficiency on cardiac electrophysiology, specifically on I Na .
Characterization of I Na in FKBP12-Deficient Cardiomyocytes
The surface ECG parameters were not altered between FKBP12 f/f /␣MyHC-Cre mice and FKBP12 f/ϩ /␣MyHC-Cre controls, except for a shorter PP interval in FKBP12-deficient hearts ( Figure 6C ] was decreased in TG hearts (nϭ7) compared with NTG hearts (nϭ6), despite similar mean resting membrane potentials (RP). Significantly longer APD at 90% repolarization (APD 90 ) was noted in TG hearts. **PϽ0.01 for NTG vs TG. APs were recorded at a pacing cycle length of 150 ms. B through F, Voltageclamp analysis of macroscopic I Na in ventricular cardiomyocytes isolated from TG (nϭ14 cells/4 hearts) and NTG (nϭ14 cell/4 hearts) hearts. B, Representative I Na traces elicited by 120 ms depolarizing pulses to potentials from Ϫ90 to ϩ30 mV from a holding potential of Ϫ100 mV at 5-mV increments (interpulse interval, 1 second). Insert shows schematic voltageclamp protocol. Bar graphs in B show meansϮSD of maximal peak I Na densities measured at Ϫ5 mV and Ϫ25 mV in TG and NTG myocytes, respectively, and whole cell capacitance (WCC). **PϽ0.01. C, Normalized I Na -V plots. Values for peak I Na density at each voltage were normalized to their respective maximal peak I Na density at Ϫ25 mV (NTG) and Ϫ5 mV (TG) and plotted as a function of voltage. D, FKBP12 overexpression slows I Na recovery from inactivation. Insert shows schematic voltage-clamp protocol. *PϽ0.05 and **PϽ0.01 vs NTG. E, Voltage dependence of steady-state I Na activation (right curves) and inactivation (left curves). F, Time course of I Na in an ␣MyHC-FKBP12 (red) and a nontransgenic ventricular cardiomyocyte.
control hearts ( Figure 7A ), suggesting an increase in I Na density. Whole-cell voltage-clamp experiments confirmed that the peak I Na density in FKBP12 f/f /␣MyHC-Cre ventricular cardiomyocytes was more than 2-fold larger than that in control cells ( Figure 7B ). The normalized I Na -V relationships for the FKBP12 f/f /␣MyHC-Cre and control cardiomyocytes were superimposable ( Figure 7C ), indicating that chronic FKBP12 deficiency did not alter the voltage dependence of I Na activation (Online Table I ). Also, the voltage dependence of steady-state inactivation and the recovery of I Na from inactivation in FKBP12 f/f /␣MyHC-Cre cardiomyocytes were not different from those in control cardiomyocytes ( Figure 7D ). Although FKBP12 deficiency accelerated both the early and late component of I Na inactivation (Online Table II) , qRT-PCR, Western blot, and immunofluorescence staining did not show significant changes in Na v 1.5 expression ( Figure 7E ). Thus, FKBP12 ablation profoundly affected peak I Na density in ventricular cardiomyocytes and altered I Na inactivation gating. In contrast to chronic FKBP12 overexpression, however, FKBP12 deficiency had no detectable effects on other gating properties of cardiac voltage-gated Na ϩ channels.
Exogenous FKBP12 Affects I Na in Isolated FKBP12 f/f /␣MyHC-Cre Ventricular Cardiomyocytes
To examine whether FKBP12 acutely regulates voltage-gated Na ϩ channels, we performed an in vitro experiment wherein FKBP12 f/f /␣MyHC-Cre cardiomyocytes were dialyzed with 1 g/L purified recombinant FKBP12 protein through a patch-pipette ( Figure 8 ). The cell was held at Ϫ100 mV and A, Ventricular cardiomyocytes from ␣MyHC-FKBP12 and wild-type mice express the TTX-resistant (cardiac isoform) but not TTX-sensitive (neuronal isoforms) of voltage-gated Na ϩ channels. Left, Representative I Na responses to increasing concentrations of extracellular TTX in TG and NTG ventricular cardiomyocytes. Right, Plots of the percentage inhibition of peak I Na as a function of TTX concentration in transgenic (nϭ4) and nontransgenic (nϭ3) myocytes. Mean Hill coefficients for TTX block of peak I Na were 1.2 and 1.3 (PϾ0.05) for the NTG and TG cardiomyocytes, suggesting that a single TTX molecule blocks a single Na ϩ channel. Nanomolar concentrations of TTX that typically block neuronal isoforms of voltage-gated Na ϩ channels had no detectable effect on peak I Na in either cardiomyocyte type. B, FKBP12 overexpression enhances a persistent Na ϩ current. Original traces of I Na elicited from Ϫ100 mV to ϩ30 mV for 400 ms before and after exposure to 3 mol/L TTX in the external solution. TTX-sensitive components were averaged over the last 100 ms of the depolarizing pulse and normalized to the cell capacitance. FKBP12 overexpression increased mean late I Na density (PϽ0.05). C, Assessment of Na v 1.5 expression and cellular localization. Western blot (a), qRT-PCR (b), and immunofluorescence and confocal imaging (c) analyses demonstrated a significant reduction of Na v 1.5 in transgenic hearts. Confocal images were representative for 3 independent sets of experiments. White arrows (in c) denote anti-Nav1.5 immune reactivity in the outer surface membrane of cardiomyocytes. **PϽ0.01.
stepped from Ϫ90 to ϩ30 mV in 5-mV increments from a holding potential of Ϫ100 mV (120 ms pulse duration, 1-second interpulse interval). I Na was recorded repeatedly for a total duration of 60 minutes. Peak I Na progressively declined to a new steady-state value during dialysis with exogenous FKBP12 (Figure 8A and 8C ). This phenomenon was not observed in cardiomyocytes dialyzed with control solution without FKBP12 ( Figure 8B and 8C) , indicating that the effect of exogenous FKBP12 in the FKBP12-deficient cell resulted from a specific FKBP12-dependent mechanism rather than from I Na run-down ( Figure 8C ). The shift of the normalized I Na -V plot in FKBP12reloaded FKPB12 f/f /␣MyHC-Cre myocytes to more positive potentials ( Figure 8D ), the slowing of I Na decay, and rightward shift of both voltage-dependent I Na activation and inactivation ( Figure 8E ; Online Table III) were similar to those observed in FKBP12-overexpressing cardiomyocytes ( Figure 3E ). The noninactivating component of I Na (y 0 in Online Table IV) measured at 45 minutes was significantly increased compared with that at 5 minutes, indicating that FKBP12 dialysis augmented a persistent I Na , which is also reflected in an increase in late I Na /peak I Na at the 45-minute time point ( Figure 8F ). Furthermore, APs and (dV/dt) max gradually prolonged and decelerated, respectively, over the course of FKPB12 dialysis (Figure 8G and 8H) . Collectively, the relatively fast onset of the effect of exogenous FKBP12 suggests that the changes in I Na density and properties seen in ␣MyHC-FKBP12 transgenic cardiomyocytes at least partially reflect acute effects of the protein on cardiac voltagegated Na ϩ channels and that FKBP12 protein loading of FKBP12-deficient cardiomyocytes closely replicates the changes in I Na density and channel gating seen in FKBP12 overexpressing myocytes.
Discussion
FKBP12 is highly expressed in the heart of diverse vertebrates including mouse and human. 7 However, the role of FKBP12 in postnatal cardiac function remained unclear. The predominant question has been whether FKBP12 plays a role in regulating RyR2. Recent work by Bers and colleagues showed that FKBP12 is unlikely to have any biological impact on RyR2 function. 6 The results of the present study indicate that FKBP12 is critically important in regulating trans-sarcolemmal ionic currents, predominately I Na . This conclusion is based on (1) an increase in peak I Na density in FKBP12-deficient cardiomyocytes; (2) a decrease in peak I Na density, but increase in late I Na density in FKBP12-overexpressed cardiomyocytes; and (3) altered I Na inactivation and recovery from inactivation and shifts of the voltage dependence of steady-state activation and inactivation to more positive potentials in ␣MyHC-FKBP12 cardiomyocytes. Importantly, acute delivery of purified FKBP12 protein to FKBP12-null myocytes recapitulated the effects of chronic FKBP12 overexpression on the density and properties of I Na , as well as on the duration and phase 0 (dV/dt) max of the AP, indicating that the effect of FKBP12 did not arise because of unspecific structural and/or functional alterations.
Loss-of-function mutations in SCN5a gene encoding Na v 1.5 lead to cardiac arrhythmias, including progressive cardiac conduction defects, 14 sick sinus syndrome, 15 and Brugada syndrome, 16 whereas gain-of-function mutations lead to type 3 long QT syndrome. 17 Combinatorial phenotypes have been reported in patients with SCN5a mutations causing both reduced peak I Na and increased late I Na . 18 Suppression of peak I Na can result in cardiac conduction disturbance 19 and abnormal sinus node function, 20 whereas increased late I Na reduces repolarization reserve and prolongs APD, which can induce early afterdepolarizations, triggered arrhythmias, and sudden cardiac death. 21 Cardiac overexpression of FKBP12 recapitulated many of the phenotypic abnormalities seen in patients with SCN5a mutations. Interestingly, the immunosuppressant FK506 has been shown to adversely affect cardiac electrophysiology, causing long QT syndrome, sinus arrest, and sudden death in patients treated with FK506. [22] [23] [24] [25] [26] [27] [28] This adverse effect was similarly demonstrated in guinea pigs. 29, 30 Bers and colleagues observed an increase in APD in FK506-treated cardiomyocytes. 31 These previous observations along with our data hint a potential role of FKBP12-mediated dysregulation of I Na as the mechanism underlying FK506-induced clinical arrhythmias.
The ionic mechanisms underlying the AV conduction abnormalities in ␣MyHC-FKBP12 mice may also involve downregulation of I Ca,L , a major determinant of conduction across the AV junction. 32 The mechanisms of I Ca,L downregulation is unclear and awaits further study. Reduction in both phase 0 (dV/dt) max and ventricular conduction velocity at near physiological rates (Figures 2 and 3 ) strongly supports the notion that the electrocardiographic manifestations of impaired ventricular conduction directly result from FKBP12 overexpression-induced reduction in net Na ϩ influx through activated voltage-gated Na ϩ channels during the initial fast depolarization of the AP. In contrast, the involvement of I Na in mediating APD prolongation in ␣MyHC-FKBP12 ventricular cardiomyocytes is less clear. Slowed I Na inactivation and the positive shift of the I Na steady-state inactivation curve would be expected to synergistically augment Na ϩ influx, increasing net inward current during the repolarizing phases of the ventricular AP, whereas the reduction in I Na density, slowing of I Na recovery, and the positive shift of the activation curve would be expected to exert the opposite effect. Although our measurements clearly demonstrate a marked increase in a persistent TTX-insensitive current in ␣MyHC-FKBP12 ventricular cardiomyocytes, it remains to be seen whether this phenomenon is solely responsible for the marked APD elongation. The observation that FKBP12 overexpression is associated with a reduction in I Ca.L and increases in I Ksus (both of which would shorten the AP) suggests that, by exclusion, I Na underlies delayed repolarization.
It is somewhat puzzling that genetic FKBP12 ablation, in contrast to FKBP12 overexpression, only affects peak I Na density and I Na inactivation kinetics, but does not significantly alter voltage dependence of I Na activation and inactivation, or I Na recovery from inactivation compared with wild-type myocytes. This may reflect the presence of multiple regulatory mechanisms with different FKBP12 sensitivities. For example, baseline levels of FKBP12 appear to be sufficient to control the number of functional channels in the sarcolemma and to regulate I Na inactivation kinetics. In contrast, higher levels of the protein seem to be required to achieve a noticeable effect on voltage dependence of I Na activation and inactivation. It would be interesting to examine whether FKBP12 expres-sion is significantly altered in the diseased heart, causing changes in excitability and conduction.
The main cardiac voltage-gated Na ϩ channel consists of a Na v 1.5 ␣-subunit and an ancillary ␤-subunit. In addition, a series of channel modulators and regulators are important to its function. 33 Our work suggests that FKBP12 is an important regulator of cardiac voltage-gated Na ϩ channels, although the exact biochemical nature that underlies the FKBP12-channel interaction remains unclear. The reduction of the peak I Na density in ␣MyHC-FKBP12 transgenic likely results from a combination of reduced Na v 1.5 protein expression and posttranslational modification of the sodium channel protein complex. The marked changes in the biophysical properties of I Na in FKBP12-deficient and transgenic cardiomyocytes suggest that FKBP12 acts directly (via proteinprotein interaction) or indirectly (via modulation of second messenger pathways) to modulate I Na . Coimmunoprecipita- tion and pull-down assays failed to demonstrate direct interaction between FKBP12 and Na v 1.5 (data not shown), suggesting that some intermediate protein(s) is mediating the interaction between FKBP12 and channel proteins. Further work is needed to identify the detailed molecular mechanism of FKBP12-channel protein interaction. In conclusion, by analyzing genetically modified mouse models, we demonstrate for the first time that FKBP12 is important for normal physiological function of the cardiac voltage-gated Na ϩ channel and is relevant to cardiac arrhythmogenesis. /L) . B, I Na remained unchanged in an FKBP12 f/f / ␣MyHC-Cre ϩ ventricular cardiomyocyte dialyzed with FKBP12-free pipette solution. C, Temporal changes in peak I Na during continuous internal dialysis with FKBP12-containing and FKBP12-free, pipette solution, respectively. D, Normalized peak I Na -V relationship at 5 and 45 minutes into FKBP12 dialysis. Internal perfusion of an FKBP12 f/f /␣MyHC-Cre ϩ ventricular cardiomyocyte with FKBP12free solution did not alter voltage dependence of I Na activation (not shown). E, Changes in voltage dependence of I Na activation and inactivation following FKBP12 application. F, The late I Na /peak I Na ratio is significantly increased following 45 minutes of FKBP12 dialysis. G, Representative AP recordings over the course of FKBP12 dialysis. Arrow indicates the gradual prolongation of APD. H, Traces of dV/dt for the same APs shown in G. Traces were shifted along the time axis for display purposes.
Novelty and Significance
What Is Known?
• FK506 binding protein (FKBP)12 and FKBP12.6 are cytosolic cis-trans peptidyl prolyl isomerases that bind to the immunosuppressants FK506 (tacrolimus) and rapamycin. • Unlike FKBP12.6, which regulates the function of type 2 ryanodine receptor (RyR2) calcium release channel, the biological function of FKBP12 in cardiomyocytes is unknown. • Treatment of transplant recipients with tacrolimus could lead to drug-induced long QT syndrome, sinus arrest, and sudden death.
What New Information Does This Article Contribute?
• FKBP12 plays an important role in regulating the electric properties of the heart, primarily via modulation of the cardiac voltage-gated sodium current, I Na . FKBP12 overexpression can lead to cardiac arrhythmias. • FKBP12-deficient cardiomyocytes exhibit increases in peak I Na density and the maximal phase 0 upstroke velocity of the action potential. • Cardiomyocytes that overexpress FKBP12 display decreased peak I Na density and increased late I Na density, which in turn led to a significant deceleration of the maximal phase 0 upstroke velocity and prolongation of the action potential prolongation, respectively. • Acute delivery of recombinant FKBP12 protein to FKBP12-deficient cardiomyocytes recapitulated the effects of chronic FKBP12 overexpression on the density and properties of I Na , as well as on the duration and the upstroke of the action potential.
Based on the structural similarities between FKBP12 and FKBP12.6, as well in vitro pharmacological studies, it has been proposed that FKBP12 is a RyR2 channel regulator. However, this hypothesis is challenged by the present study, which used genetic loss-of-function and gain-of-function models coupled with systematic in vivo and in vitro physiological analyses. The results of these studies showing that FKBP12 is important in regulating the expression and the function of the cardiac voltage-gated sodium channel suggest that the major biological function of FKBP12 is unlikely to involve regulation of RyR2. When FKBP12 was overexpressed, peak I Na was reduced and the late I Na component was increased, resulting in a decrease in conduction velocity, longer action potential duration, and sudden cardiac death. These findings may explain the clinical observation that a subset of transplant patients receiving tacrolimus develops long QT syndrome and cardiac arrhythmias. Further studies of FKBP12 function in the heart may provide new insights into inherited arrhythmia syndromes such as Brugada syndrome, progressive conduction system diseases, and type 3 long QT syndrome. Furthermore, abnormalities of FKBP12 (and/or its upstream and downstream effectors) may play a role in the mechanisms of common cardiac arrhythmias such as atrial fibrillation and sudden death.
